TLDR:
Regeneron Ventures has launched a $500 million venture capital fund focused on investing in promising biopharmaceutical, health care, and health technology companies. The fund’s general partner will be managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who will lead the investment strategy. Regeneron Pharmaceuticals is the exclusive limited partner, committing $100 million annually for five years. Drs. Markowitz and Aberman bring extensive experience in both biotech and investing to the fund, with a patient-centric focus and commitment to advancing science and medicine.
Article Summary:
Regeneron Ventures has announced the launch of a new $500 million venture capital fund aimed at investing in promising biopharmaceutical, health care, and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who will work together to lead the fund’s investment strategy.
Regeneron Pharmaceuticals is the fund’s exclusive limited partner and has committed $100 million annually for five years to support the fund’s investments. Drs. Markowitz and Aberman have extensive experience in the biotech industry and investing, with a focus on patient-centric missions and a commitment to advancing science and medicine.
Before joining Regeneron Ventures, Michael Aberman, M.D., was CEO and Co-founder of XenImmune Therapeutics, a seed-stage biotech company, and had previously held leadership roles at other biotech companies. Jay Markowitz, M.D., joined Regeneron Ventures from ARCH Venture Partners, where he founded multiple companies and served as a board member and advisor.
Both Drs. Markowitz and Aberman bring a wealth of experience and knowledge to Regeneron Ventures, aiming to support groundbreaking advancements in science and medicine through the fund’s investments. Their goal is to create an ecosystem where the next generation of biotech companies can thrive and push the boundaries of what is possible in the industry.
The fund will focus on investing for the long-term, regardless of therapeutic area, technology, or stage of development, in order to support transformative approaches to preventing and treating diseases. Regeneron Ventures aims to leverage the success and lessons learned at Regeneron and throughout the executives’ careers to identify and support innovative companies that drive progress in the biotech sector.
Key Quotes:
“Understanding that the most groundbreaking, transformative approaches to preventing and treating disease may yet to be discovered, the fund will invest for the long-term, agnostic to therapeutic area, technology and stage of development
